Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lieberman

Showing results (701-710 of 1,142) with videos related to

Pageof 115
Sort By:
The Journal of Clinical Psychiatry|July 1, 1988
Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugsJ A Lieberman, C A Johns, J M Kane, et al.
Schizophrenia Research|April 6, 2004
Secretin for refractory schizophreniaBrian B Sheitman, Michael B Knable, L Fredrik Jarskog, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 11, 2024
Patient-Centered Practice Guidelines: GRADEing Evidence to Incorporate Certainty, Balance Between Benefits and Harms, Equity, Feasibility, and Cost-EffectivenessEllen Stephen, Alexandra E Conway, Christopher D Codispoti, et al.
Gastrointestinal Endoscopy|May 27, 2011
Adenoma detection rate increases with each decade of life after 50 years of ageSarah J Diamond, Brintha K Enestvedt, Zibing Jiang, et al.
The American Journal of Gastroenterology|February 22, 2018
Family history of colorectal cancer in first-degree relatives and metachronous colorectal adenomaElizabeth T Jacobs, Samir Gupta, John A Baron, et al.
The Journal of Clinical Psychiatry|November 6, 2002
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch studyJean-Pierre Lindenmayer, Pal Czobor, Jan Volavka, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|February 21, 2008
The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognitionJames J Crowley, Richard S E Keefe, Diana O Perkins, et al.
Archives of Neurology|December 1, 1994
Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergolineJ E Ahlskog, M D Muenter, D M Maraganore, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 27, 2014
IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cellsMasayuki Mizui, Tomohiro Koga, Linda A Lieberman, et al.
The Pharmacogenomics Journal|January 5, 2018
Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapineFrançois R Girardin, Antoine Poncet, Arnaud Perrier, et al.
Pageof 115

Showing results (701-710 of 1,142) with videos related to

Sort By:
Pageof 115
The Journal of Clinical Psychiatry|July 1, 1988
Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugsJ A Lieberman, C A Johns, J M Kane, et al.
Schizophrenia Research|April 6, 2004
Secretin for refractory schizophreniaBrian B Sheitman, Michael B Knable, L Fredrik Jarskog, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 11, 2024
Patient-Centered Practice Guidelines: GRADEing Evidence to Incorporate Certainty, Balance Between Benefits and Harms, Equity, Feasibility, and Cost-EffectivenessEllen Stephen, Alexandra E Conway, Christopher D Codispoti, et al.
Gastrointestinal Endoscopy|May 27, 2011
Adenoma detection rate increases with each decade of life after 50 years of ageSarah J Diamond, Brintha K Enestvedt, Zibing Jiang, et al.
The American Journal of Gastroenterology|February 22, 2018
Family history of colorectal cancer in first-degree relatives and metachronous colorectal adenomaElizabeth T Jacobs, Samir Gupta, John A Baron, et al.
The Journal of Clinical Psychiatry|November 6, 2002
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch studyJean-Pierre Lindenmayer, Pal Czobor, Jan Volavka, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|February 21, 2008
The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognitionJames J Crowley, Richard S E Keefe, Diana O Perkins, et al.
Archives of Neurology|December 1, 1994
Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergolineJ E Ahlskog, M D Muenter, D M Maraganore, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 27, 2014
IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cellsMasayuki Mizui, Tomohiro Koga, Linda A Lieberman, et al.
The Pharmacogenomics Journal|January 5, 2018
Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapineFrançois R Girardin, Antoine Poncet, Arnaud Perrier, et al.
Pageof 115